Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets

Small-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, invariably relapses and acquires a multidrug chemoresistant phenotype that generally renders retreatment with first-line therapy both futile and counterproductive. This report presents the case of a 77-...

Full description

Bibliographic Details
Main Authors: Corey A. Carter, Bryan Oronsky, Scott Caroen, Jan Scicinski, Aiste Degesys, Pedro Cabrales, Tony R. Reid, Christina Brzezniak
Format: Article
Language:English
Published: Karger Publishers 2016-05-01
Series:Case Reports in Oncology
Subjects:
Partial response
RRx-001
Refractory small-cell lung cancer
Platinum doublets
Online Access:http://www.karger.com/Article/FullText/446209

Internet

http://www.karger.com/Article/FullText/446209

Similar Items